RLAY Valuation

Relay Therapeutics Inc

Add to Watchlist

Advanced Chart

3.590

-0.1(-2.710%)1D

Overview
Forecast
Valuation
Earnings

RLAY Relative Valuation

RLAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RLAY is overvalued; if below, it's undervalued.

Historical Valuation

Relay Therapeutics Inc (RLAY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.17. The fair price of Relay Therapeutics Inc (RLAY) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.54

Fair

-2.37

Trailing

Forward

-0.05

EV/EBITDA

Relay Therapeutics Inc. (RLAY) has a current EV/EBITDA of -0.05. The 5-year average EV/EBITDA is -5.36. The thresholds are as follows: Strongly Undervalued below -20.05, Undervalued between -20.05 and -12.70, Fairly Valued between 1.99 and -12.70, Overvalued between 1.99 and 9.33, and Strongly Overvalued above 9.33. The current Forward EV/EBITDA of -0.05 falls within the Historic Trend Line -Fairly Valued range.

-0.04

EV/EBIT

Relay Therapeutics Inc. (RLAY) has a current EV/EBIT of -0.04. The 5-year average EV/EBIT is -5.73. The thresholds are as follows: Strongly Undervalued below -22.55, Undervalued between -22.55 and -14.14, Fairly Valued between 2.69 and -14.14, Overvalued between 2.69 and 11.10, and Strongly Overvalued above 11.10. The current Forward EV/EBIT of -0.04 falls within the Historic Trend Line -Fairly Valued range.

109.32

Relay Therapeutics Inc. (RLAY) has a current PS of 109.32. The 5-year average PS is 932.67. The thresholds are as follows: Strongly Undervalued below -1602.29, Undervalued between -1602.29 and -334.81, Fairly Valued between 2200.16 and -334.81, Overvalued between 2200.16 and 3467.64, and Strongly Overvalued above 3467.64. The current Forward PS of 109.32 falls within the Historic Trend Line -Fairly Valued range.

-3.17

P/OCF

Relay Therapeutics Inc. (RLAY) has a current P/OCF of -3.17. The 5-year average P/OCF is -11.87. The thresholds are as follows: Strongly Undervalued below -37.13, Undervalued between -37.13 and -24.50, Fairly Valued between 0.76 and -24.50, Overvalued between 0.76 and 13.39, and Strongly Overvalued above 13.39. The current Forward P/OCF of -3.17 falls within the Historic Trend Line -Fairly Valued range.

-2.78

P/FCF

Relay Therapeutics Inc. (RLAY) has a current P/FCF of -2.78. The 5-year average P/FCF is -10.67. The thresholds are as follows: Strongly Undervalued below -30.55, Undervalued between -30.55 and -20.61, Fairly Valued between -0.73 and -20.61, Overvalued between -0.73 and 9.21, and Strongly Overvalued above 9.21. The current Forward P/FCF of -2.78 falls within the Historic Trend Line -Fairly Valued range.

Relay Therapeutics Inc (RLAY) has a current Price-to-Book (P/B) ratio of 0.95. Compared to its 3-year average P/B ratio of 1.50 , the current P/B ratio is approximately -36.71% higher. Relative to its 5-year average P/B ratio of 2.54, the current P/B ratio is about -62.47% higher. Relay Therapeutics Inc (RLAY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -27.13%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -17.58% , the current FCF yield is about -100.00% lower.

0.95

P/B

Median3y

1.50

Median5y

2.54

-41.19

FCF Yield

Median3y

-27.13

Median5y

-17.58

Competitors Valuation Multiple

The average P/S ratio for RLAY's competitors is 37.67, providing a benchmark for relative valuation. Relay Therapeutics Inc Corp (RLAY) exhibits a P/S ratio of 109.32, which is 190.23% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RLAY.O

Relay Therapeutics Inc

Vir Biotechnology Inc

MeiraGTx Holdings PLC

Maravai LifeSciences Holdings Inc

Performance Decomposition

Market capitalization of RLAY decreased by 45.66% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 677.00K.

The secondary factor is the Margin Expansion, contributed 499.22%to the performance.

Overall, the performance of RLAY in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 677.00K

Revenue Growth

499.22%

-1.73K → -10.40K

Margin Expansion

NaN%

0.00 → -1.92

P/E Change

-45.66%